Pharmaceuticals - Political pressure

RECENT NEWS
Wall Street Journal  Aug 28  Comment 
Dallas Fed President Robert Kaplan discussed his outlook on trade disputes, political pressure and the prospect of additional interest-rate increases this year in Jackson Hole.
Yahoo  Aug 19  Comment 
Iran will unveil a new fighter jet this week as part of the nation’s plan to boost its defense capability, Defense Minister Brigadier General Amir Hatami said, in a show of force as the country faces bruising new U.S. sanctions. Hatami spoke...
Financial Times  Aug 15  Comment 
Financial Reporting Council caves to political pressure to publish full report
Yahoo  Jul 11  Comment 
The UK's privacy watchdog revealed yesterday that it intends to fine Facebook
New York Times  Jun 22  Comment 
Under political pressure, Angela Merkel secured the help of the European Commission to call an unusual weekend meeting on how to manage migration.
MarketWatch  May 25  Comment 
The confidence vote, filed by the center-left Socialist Party and supported by the far-left Podemos, adds to mounting political pressure that is weakening Rajoy’s minority government
New York Times  May 24  Comment 
The comments came as administration officials bowed to political pressure to change plans to share highly classified information about an informant in the Russia inquiry with Congress.
Reuters  Mar 29  Comment 
A Federal Reserve policymaker pushed back on calls from two U.S. senators for the nominee to a high-profile job at the Fed to testify before Congress, saying such a rule could hurt the central bank's independence from political pressure.
Financial Times  Mar 19  Comment 
Companies are under investor and political pressure to improve governance
Channel News Asia  Mar 16  Comment 
The Federal Reserve Bank of New York is considering a "handful" of candidates for what is seen as the second most influential job at the U.S. central bank, its directors said on Friday, as political pressure mounts to choose someone who breaks...




 
TOP CONTRIBUTORS

Prescription drug prices are often brought up in debates about the U.S. health care system as a whole. Many claim that pharmaceutical companies overcharge for their prescription drugs, making quality healthcare too expensive for some to afford. Drug companies cite the high costs of drug development as the reason for high end-user prices. They also often decry the length of patent protection, saying that they have to recoup all the money spent on development within a relatively limited period of time, forcing them to charge higher prices. Nonetheless, there is growing political pressure to lower prescription drug prices and relax the restrictions on generic drug production, despite pharmaceutical companies' warnings that this could slow or hinder the development of life-saving drugs.

An example of this political pressure is the recent bill passed by the House of Representatives aimed at lowering prescription drug costs for Medicare recipients. The bill repealed a previous provision that prevented the Secretary of Health and Human Services from negotiating with drug companies on behalf of Medicare recipients. Instead, the new bill requires that the Secretary conduct such price negotiations. This is aimed at lowering costs for Americans enrolled in Medicare prescription drug plans, though it would save the government money as well.

US Federal Reserve chairman Ben Bernanke warned of rising health costs and the effect it may have on the government budget. Lower income households would be the hardest hit because they depend the most on government help.[1]

Companies that benefit from increased regulation of pharmaceuticals

Health insurance companies

Companies hurt by increased regulation of pharmaceuticals

Pharmaceutical companies

The drug development process is costly and time-consuming, taking an average of $800 million and several years to develop just one commercially viable drug. Pharmaceutical companies cite these as reasons why they're forced to charge seemingly exorbitant prices for their products. If political pressure were to lead to increased regulation of drug prices or a relaxing of rules governing generics, large pharmaceutical companies would be negatively impacted.

Among the biggest issues facing the industry is the meaningful decline in the pace of new drug introductions combined with the pending patent expiration of some of the highest revenue producing drugs in the industry. Merck is likely to lose 25% of its revenue to patent expiration over the next 3 years, drugs like Vasotec, Prinivil, Pepsid, and Prilosec. Pfizer faces the patent expiration of Lipitor, it's $13 billion blockbuster, in 2011. Patented drugs are coming off patent faster than new drugs are being patented. This is steadily eroding the profitability of the industry as price per pill declines dramatically upon the introduction of generic competition, and operating margins move into the single digits. Firms are reacting with cuts in R&D and Sales Expenses, and are finding growth through acquisition and the economies of scale of size. The largest firms are moving toward a model that recognizes their core strength as distribution while innovation is purchased on the outside.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki